SG2014009278A - Novel imidazole amines as modulators of kinase activity - Google Patents

Novel imidazole amines as modulators of kinase activity

Info

Publication number
SG2014009278A
SG2014009278A SG2014009278A SG2014009278A SG2014009278A SG 2014009278 A SG2014009278 A SG 2014009278A SG 2014009278 A SG2014009278 A SG 2014009278A SG 2014009278 A SG2014009278 A SG 2014009278A SG 2014009278 A SG2014009278 A SG 2014009278A
Authority
SG
Singapore
Prior art keywords
modulators
kinase activity
novel imidazole
imidazole amines
amines
Prior art date
Application number
SG2014009278A
Other languages
English (en)
Inventor
Ruoxi Lan
Bayard R Huck
Xiaoling Chen
Yufang Xiao
Lizbeth Celeste Deselm
Hui Qiu
Constantin Neagu
Donald Bankston
Christopher Charles Victor Jones
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG2014009278A publication Critical patent/SG2014009278A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
SG2014009278A 2011-09-12 2012-09-12 Novel imidazole amines as modulators of kinase activity SG2014009278A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161533601P 2011-09-12 2011-09-12
PCT/US2012/054900 WO2013040059A1 (en) 2011-09-12 2012-09-12 Novel imidazole amines as modulators of kinase activity

Publications (1)

Publication Number Publication Date
SG2014009278A true SG2014009278A (en) 2014-07-30

Family

ID=46881179

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2014009278A SG2014009278A (en) 2011-09-12 2012-09-12 Novel imidazole amines as modulators of kinase activity
SG10201606301YA SG10201606301YA (en) 2011-09-12 2012-09-12 Novel imidazole amines as modulators of kinase activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201606301YA SG10201606301YA (en) 2011-09-12 2012-09-12 Novel imidazole amines as modulators of kinase activity

Country Status (24)

Country Link
US (2) US9145392B2 (enExample)
EP (1) EP2755965B1 (enExample)
JP (1) JP5964974B2 (enExample)
KR (1) KR101995605B1 (enExample)
CN (1) CN104080782B (enExample)
AU (1) AU2012308696B2 (enExample)
BR (1) BR112014005554A2 (enExample)
CA (1) CA2844830C (enExample)
DK (1) DK2755965T3 (enExample)
EA (1) EA025098B1 (enExample)
ES (1) ES2644536T3 (enExample)
HR (1) HRP20171554T1 (enExample)
HU (1) HUE035019T2 (enExample)
IL (1) IL231383A (enExample)
LT (1) LT2755965T (enExample)
MX (1) MX346095B (enExample)
NO (1) NO2791461T3 (enExample)
PL (1) PL2755965T3 (enExample)
PT (1) PT2755965T (enExample)
RS (1) RS56534B1 (enExample)
SG (2) SG2014009278A (enExample)
SI (1) SI2755965T1 (enExample)
WO (1) WO2013040059A1 (enExample)
ZA (1) ZA201401013B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6082011B2 (ja) * 2011-09-12 2017-02-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung キナーゼ活性のモジュレーターとして使用するためのアミノピリミジン誘導体
EA027277B1 (ru) 2012-10-16 2017-07-31 Альмираль, С.А. Производные пирроллотриазинона в качестве ингибиторов pi3k
AU2013344549B2 (en) 2012-11-16 2018-03-08 Xiaoling Chen Novel imidazol-piperidinyl derivatives as modulators of kinase activity
HK1218756A1 (zh) 2013-03-11 2017-03-10 默克专利有限公司 用作激酶活性调节剂的6-[4-(1h-咪唑-2-基)哌啶-1-基]嘧啶-4-胺衍生物
SG11201605121VA (en) * 2014-02-11 2016-07-28 Merck Patent Gmbh Pyrimidine imidazole amines as modulators of kinase activity
JP6529085B2 (ja) 2014-04-18 2019-06-12 武田薬品工業株式会社 複素環化合物
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药(上海)有限公司 环烯烃取代的杂芳环类化合物及其用途
KR20200093159A (ko) 2019-01-28 2020-08-05 주식회사 링크모션 스마트 팜 모듈 구조물
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
US11866421B2 (en) 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
DK4347031T3 (da) 2021-06-04 2025-12-01 Vertex Pharma N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler
CN117567435A (zh) * 2022-01-30 2024-02-20 上海市第十人民医院 谷氨酰胺环化酶抑制剂及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
AU2004230841A1 (en) 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AU2004278413B2 (en) 2003-09-30 2008-07-31 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2004283751B2 (en) 2003-10-24 2011-05-19 Exelixis, Inc. p70S6 kinase modulators and method of use
WO2005054237A1 (en) 2003-11-21 2005-06-16 Novartis Ag 1h-imidazoquinoline derivatives as protein kinase inhibitors
CN1889958A (zh) 2003-12-09 2007-01-03 美国政府健康及人类服务部 抑制免疫应答或治疗增生性疾病的方法
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
CA2590961C (en) 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
AU2006206246A1 (en) * 2005-01-19 2006-07-27 Neurogen Corporation Heteroaryl substituted piperazinyl-pyridine analogues
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
EP2396307B1 (en) 2009-02-11 2014-10-15 Merck Patent GmbH Novel amino azaheterocyclic carboxamides
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
CA2803387C (en) 2010-07-29 2017-12-05 Bayard R. Huck Cyclic amine azaheterocyclic carboxamides
WO2012069146A1 (en) 2010-11-24 2012-05-31 Merck Patent Gmbh Quinazoline carboxamide azetidines

Also Published As

Publication number Publication date
JP5964974B2 (ja) 2016-08-03
EP2755965B1 (en) 2017-07-26
MX2014002832A (es) 2014-05-27
BR112014005554A2 (pt) 2017-03-21
EA025098B1 (ru) 2016-11-30
US9145392B2 (en) 2015-09-29
US20160000785A1 (en) 2016-01-07
EA201400339A1 (ru) 2014-08-29
IL231383A0 (en) 2014-04-30
LT2755965T (lt) 2017-11-10
HUE035019T2 (en) 2018-03-28
RS56534B1 (sr) 2018-02-28
CN104080782A (zh) 2014-10-01
CA2844830C (en) 2019-09-10
DK2755965T3 (en) 2017-09-25
JP2014531436A (ja) 2014-11-27
CN104080782B (zh) 2016-06-01
ES2644536T3 (es) 2017-11-29
IL231383A (en) 2017-11-30
EP2755965A1 (en) 2014-07-23
HK1201825A1 (zh) 2015-09-11
SG10201606301YA (en) 2016-09-29
HRP20171554T1 (hr) 2017-11-17
KR101995605B1 (ko) 2019-07-02
PL2755965T3 (pl) 2018-01-31
US20140343029A1 (en) 2014-11-20
WO2013040059A1 (en) 2013-03-21
ZA201401013B (en) 2018-07-25
NO2791461T3 (enExample) 2018-07-21
AU2012308696B2 (en) 2017-04-27
CA2844830A1 (en) 2013-03-21
AU2012308696A1 (en) 2014-02-27
KR20140063694A (ko) 2014-05-27
SI2755965T1 (sl) 2017-12-29
MX346095B (es) 2017-03-07
PT2755965T (pt) 2017-11-02

Similar Documents

Publication Publication Date Title
ZA201401013B (en) Novel imidazole amines as modulators of kinase activity
AP4075A (en) Novel compounds as modulators of protein kinases
ZA201401007B (en) Aminopyrimidine derivative for use as modulators of kinase activity
AP4029A (en) Inhibitors of beta-secretase
IL228103A0 (en) Amino-quinolines as kinase inhibitors
IL228945A0 (en) Modified bicyclylmethylamine derivatives as sphingosine-1-phosphate receptor modulators
EP2836479A4 (en) USE OF NEW AMINES FOR STABILIZING QUATERNARY TRIALKYLALCANOLAMINES
PL2753330T3 (pl) Terapeutyczne zastosowania ektoiny
SG11201405606RA (en) Method for preparation of medetomidine
IL236963A0 (en) beta-secretase inhibitors
ZA201403517B (en) Novel heterocyclic carboxamides as modulators of kinase activity
IL243729A0 (en) Novel modulators of protein kinases
GB2494923B (en) Set of support assemblies
ZA201105238B (en) Levelling of supports